FDA Approves Rituximab Biosimilar for Hematologic Malignancies and Autoimmune Diseases

The U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar, developed by Dr. Reddy's Laboratories and to be commercialized by Fresenius Kabi, for the treatment of various hematologic malignancies and autoimmune diseases. This approval is expected to enhance patient access to high-quality, affordable biologic medicines in the U.S. market.